Clinical Trial Update: Three Different Doses of Neostigmine on the Reversal of Cisatracurium-induced Moderate Neuromuscular Blockade [Phase 4]

View source ↗

Summary

A Phase 4 trial assessing three different doses of neostigmine to reverse cisatracurium-induced moderate neuromuscular blockade.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromuscular Blockade

Drugs mentioned

• Cisatracurium (Cisatracurium besylate)
• Neostigmine (neostigmine)

Snippet

Sponsor: Pontificia Universidade Catolica de Sao Paulo | Conditions: Neuromuscular Blockade, Neuromuscular Blockade, Residual | Phase 4 | Status: UNKNOWN